Abstract
Quinolones are among the most common frameworks present in the bioactive molecules and hence represent an attractive starting point for the design of combinatorial libraries. Since 1962 4-quinolone-3-carboxylic acid derivatives are clinically used as antibacterial agents worldwide. Currently, fluoroquinolones are approved by the WHO as second-line drugs to treat tuberculosis (TB), and their use in multidrug-resistant (MDR)-TB is increasing due to the fact that they have a broad and potent spectrum of activity and can be administered orally. In the last years, quinolones endowed with “nonclassical” biological activities, such as antitumor, anti-HIV-1 integrase, cannabinoid receptor 2 agonist/antagonist activities, have been reported by our research group as well as by other researchers. This review focuses on the 4-quinolone-3- carboxylic acid motif as a privileged structure in medicinal chemistry for obtaining new compounds possessing antibacterial, antitumor, anti-HIV, and cannabinoid receptors modulating activities. Synthetic approaches, structure-activity relationships, mechanisms of action, and therapeutic potentials of these novel classes of pharmacologically active compounds are presented.
Keywords: Quinolones, HIV-1 integrase inhibitors, anti-tumor agents, CB2 agonists, drug design, privileged structure
Current Medicinal Chemistry
Title: The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry
Volume: 16 Issue: 14
Author(s): Claudia Mugnaini, Serena Pasquini and Federico Corelli
Affiliation:
Keywords: Quinolones, HIV-1 integrase inhibitors, anti-tumor agents, CB2 agonists, drug design, privileged structure
Abstract: Quinolones are among the most common frameworks present in the bioactive molecules and hence represent an attractive starting point for the design of combinatorial libraries. Since 1962 4-quinolone-3-carboxylic acid derivatives are clinically used as antibacterial agents worldwide. Currently, fluoroquinolones are approved by the WHO as second-line drugs to treat tuberculosis (TB), and their use in multidrug-resistant (MDR)-TB is increasing due to the fact that they have a broad and potent spectrum of activity and can be administered orally. In the last years, quinolones endowed with “nonclassical” biological activities, such as antitumor, anti-HIV-1 integrase, cannabinoid receptor 2 agonist/antagonist activities, have been reported by our research group as well as by other researchers. This review focuses on the 4-quinolone-3- carboxylic acid motif as a privileged structure in medicinal chemistry for obtaining new compounds possessing antibacterial, antitumor, anti-HIV, and cannabinoid receptors modulating activities. Synthetic approaches, structure-activity relationships, mechanisms of action, and therapeutic potentials of these novel classes of pharmacologically active compounds are presented.
Export Options
About this article
Cite this article as:
Mugnaini Claudia, Pasquini Serena and Corelli Federico, The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry, Current Medicinal Chemistry 2009; 16 (14) . https://dx.doi.org/10.2174/092986709788186156
DOI https://dx.doi.org/10.2174/092986709788186156 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Safer, Greener, and More Facile Alternatives for Synthesis with Organic Azides
Current Organic Synthesis Effective Delivery Routes and Strategies for Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC)
Current Pharmaceutical Design The -omics Era- Toward a Systems-Level Understanding of Streptomyces
Current Genomics Bifunctional Anti-HIV/TB Inhibitors: Perspective from In-Silico Design and Molecular Dynamics Simulations
Letters in Drug Design & Discovery The Role of Vitamin D in Atherosclerosis Inflammation Revisited: More a Bystander than a Player?
Current Vascular Pharmacology Atranorin – An Interesting Lichen Secondary Metabolite
Mini-Reviews in Medicinal Chemistry Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs)
Anti-Cancer Agents in Medicinal Chemistry Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Recent Advances in Understanding and Management of Chronic Granulomatous Disease
Current Immunology Reviews (Discontinued) MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Current Medicinal Chemistry Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Multiplication of <i>Mycobacterium tuberculosis</i> in Peripheral Blood of Mice and Effect of Anti-tubercular Drugs on Bacteremia
Letters in Drug Design & Discovery The Mycobacterial HBHA Protein: A Promising Biomarker for Tuberculosis
Current Medicinal Chemistry Transcriptional Regulation and Expression of CYP3A4 in Hepatocytes
Current Drug Metabolism Exosomes: Critical Mediators of Tumour Microenvironment Reprogramming
Current Medicinal Chemistry Meet Our Associate Editor
Current Drug Metabolism Medicinal Chemistry of ATP Synthase: A Potential Drug Target of Dietary Polyphenols and Amphibian Antimicrobial Peptides
Current Medicinal Chemistry High Throughput Screening of 7-Methylpicene-1,2-Diol as Arylamine N-Acetyltransferase (NAT) Inhibitor to Establish a Isoniazid Supplement in Anti-Tubercular Therapy
Combinatorial Chemistry & High Throughput Screening Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases
Current Pharmaceutical Design